1. Home
  2. SILO
  3. SILO News

Latest Silo Pharma Inc. (SILO) News on September 11, 2025

SILO

MT Newswires

3 months ago

Silo Pharma, Hoth Therapeutics to Launch Joint Venture for Obesity Treatment

Silo Pharma Enters into Letter of Intent to Form Joint Venture with Hoth Therapeutics to Develop Obesity Treatment Targeting $16 Billion Global Market
SILO

GlobeNewswire

3 months ago

Silo Pharma Enters into Letter of Intent to Form Joint Venture with Hoth Therapeutics to Develop Obesity Treatment Targeting $16 Billion Global Market

Hoth Therapeutics (HOTH) and Silo Pharma (NASDAQ: SILO) today announced the formation of a 50/50 joint venture to develop a first-in-class GDNF-based therapy licensed from the U.S. Department of Veterans Affairs. The therapy targets obesity and fatty liver disease.
SILO

PR Newswire

3 months ago

Hoth Therapeutics (HOTH) and Silo Pharma (NASDAQ: SILO) today announced the formation of a 50/50 joint venture to develop a first-in-class GDNF-based therapy licensed from the U.S. Department of Veterans Affairs. The therapy targets obesity and fatty liver disease.

SILO

Market Exclusive

3 months ago

Weekly Roundup on the Cannabis Sector & Psychedelic Sector

Silo Pharma Secures Biomarker Patent for Novel PTSD Therapeutic SPC-15 as Clinical Trial Nears
SILO

GlobeNewswire

3 months ago

Silo Pharma Secures Biomarker Patent for Novel PTSD Therapeutic SPC-15 as Clinical Trial Nears

Silo Pharma Partners with Resyca for IND-Supporting Intranasal Drug-Device Study of PTSD Drug SPC-15
SILO

GlobeNewswire

4 months ago

Silo Pharma Partners with Resyca for IND-Supporting Intranasal Drug-Device Study of PTSD Drug SPC-15

Silo Pharma Announces Closing of $2 Million Public Offering
SILO

GlobeNewswire

4 months ago

Silo Pharma Announces Closing of $2 Million Public Offering

Silo Pharma Announces Pricing of $2 Million Public Offering
SILO

GlobeNewswire

4 months ago

Silo Pharma Announces Pricing of $2 Million Public Offering

Silo Pharma Selects Veloxity Labs for Bioanalytical IND-Enabling Study for our Novel Intranasal PTSD Therapy, SPC-15
SILO

GlobeNewswire

4 months ago

Silo Pharma Selects Veloxity Labs for Bioanalytical IND-Enabling Study for our Novel Intranasal PTSD Therapy, SPC-15

Silo Pharma Advances PTSD Drug SPC-15 Toward First-in-Human Trial with Key Safety Study Initiated at Frontage Laboratories
SILO

GlobeNewswire

4 months ago

Silo Pharma Advances PTSD Drug SPC-15 Toward First-in-Human Trial with Key Safety Study Initiated at Frontage Laboratories

Silo Pharma’s SP-26 Ketamine Implant Meets All Endpoints in Fibromyalgia Study
SILO

GlobeNewswire

4 months ago

Silo Pharma’s SP-26 Ketamine Implant Meets All Endpoints in Fibromyalgia Study

Silo Pharma Expands Intellectual Property Portfolio with Patent Application for Exclusively Licensed Alzheimer’s Drug
SILO

GlobeNewswire

4 months ago

Silo Pharma Expands Intellectual Property Portfolio with Patent Application for Exclusively Licensed Alzheimer’s Drug

Silo Pharma Achieves Key Milestone with First Dosing in IND-Enabling GLP Study for SPC-15 as a Groundbreaking PTSD Treatment
SILO

GlobeNewswire

6 months ago

Silo Pharma Achieves Key Milestone with First Dosing in IND-Enabling GLP Study for SPC-15 as a Groundbreaking PTSD Treatment

Psychedelic: GH Research, Compass Pathways report earnings results
SILO

TipRanks

6 months ago

Psychedelic: GH Research, Compass Pathways report earnings results

Silo Pharma Granted U.S. Patent for Novel Intranasal Post-Traumatic Stress Disorder Treatment
SILO

GlobeNewswire

7 months ago

Silo Pharma Granted U.S. Patent for Novel Intranasal Post-Traumatic Stress Disorder Treatment

Silo Pharma Expands Intellectual Property Portfolio with Provisional Patent Filing for Innovative SPC-15 Combination Treatment
SILO

GlobeNewswire

7 months ago

Silo Pharma Expands Intellectual Property Portfolio with Provisional Patent Filing for Innovative SPC-15 Combination Treatment

Silo Pharma Announces Positive Initial Pharmacokinetic, Safety, and Tolerability Study of SP-26 for Chronic Pain and Fibromyalgia
SILO

GlobeNewswire

7 months ago

Silo Pharma Announces Positive Initial Pharmacokinetic, Safety, and Tolerability Study of SP-26 for Chronic Pain and Fibromyalgia

Silo Pharma Advances Intellectual Property Portfolio with Provisional Patent Filing for PTSD Treatment
SILO

GlobeNewswire

8 months ago

Silo Pharma Advances Intellectual Property Portfolio with Provisional Patent Filing for PTSD Treatment

Silo Pharma awarded U.S. patent for PTSD treatment
SILO

TipRanks

8 months ago

Silo Pharma awarded U.S. patent for PTSD treatment

Silo Pharma Awarded US Patent for Groundbreaking PTSD Treatment and Prepares for SPC-15 Clinical Trial
SILO

GlobeNewswire

8 months ago

Silo Pharma Awarded US Patent for Groundbreaking PTSD Treatment and Prepares for SPC-15 Clinical Trial

Silo Pharma Issues Letter to Shareholders Detailing Development Progress and Potential for Lead Assets Targeting PTSD and Chronic Pain
SILO

GlobeNewswire

8 months ago

Silo Pharma Issues Letter to Shareholders Detailing Development Progress and Potential for Lead Assets Targeting PTSD and Chronic Pain

Silo Pharma initiates pharmacokinetic, tolerability study for SP-26
SILO

TipRanks

9 months ago

Silo Pharma initiates pharmacokinetic, tolerability study for SP-26

Silo Pharma Initiates Pharmacokinetic and Tolerability Study for SP-26 Targeting Chronic Pain and Fibromyalgia
SILO

GlobeNewswire

9 months ago

Silo Pharma Initiates Pharmacokinetic and Tolerability Study for SP-26 Targeting Chronic Pain and Fibromyalgia

Silo Pharma Enters Joint Development Agreement for SP-26 Ketamine Implant Device Targeting Pain Management
SILO

GlobeNewswire

9 months ago

Silo Pharma Enters Joint Development Agreement for SP-26 Ketamine Implant Device Targeting Pain Management

Silo Pharma Announces Positive Results for Novel SPC-15 Treatment Targeting Stress-Related Disorders
SILO

GlobeNewswire

10 months ago

Silo Pharma Announces Positive Results for Novel SPC-15 Treatment Targeting Stress-Related Disorders

Silo Pharma Third Quarter 2024 Earnings: US$0.22 loss per share (vs US$0.21 loss in 3Q 2023)
SILO

Simply Wall St.

10 months ago

Silo Pharma Third Quarter 2024 Earnings: US$0.22 loss per share (vs US$0.21 loss in 3Q 2023)

Silo Pharma Reports Positive Results in Sterilization and Dissolution Testing of SP-26 Ketamine Implant
SILO

GlobeNewswire

10 months ago

Silo Pharma Reports Positive Results in Sterilization and Dissolution Testing of SP-26 Ketamine Implant

Silo Pharma Announces Completion of FDA Pre-IND Meeting to Advance Development of SPC-15 for Treatment of PTSD
SILO

GlobeNewswire

a year ago

Silo Pharma Announces Completion of FDA Pre-IND Meeting to Advance Development of SPC-15 for Treatment of PTSD

Silo Pharma Expands Development Agreement with Sever Pharma for Novel Ketamine Implant Therapeutic
SILO

GlobeNewswire

a year ago

Silo Pharma Expands Development Agreement with Sever Pharma for Novel Ketamine Implant Therapeutic

Silo Pharma Announces Partnership with Global CRO for Central Nervous System Homing Peptide
SILO

GlobeNewswire

a year ago

Silo Pharma Announces Partnership with Global CRO for Central Nervous System Homing Peptide

Silo Pharma to Present at H.C. Wainwright Annual Global Investment Conference
SILO

GlobeNewswire

a year ago

Silo Pharma to Present at H.C. Wainwright Annual Global Investment Conference

Silo Pharma Announces Closing of $2.1 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
SILO

GlobeNewswire

a year ago

Silo Pharma Announces Closing of $2.1 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules

Silo Pharma Announces $2.1 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
SILO

GlobeNewswire

a year ago

Silo Pharma Announces $2.1 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules

Silo Pharma and Resyca BV Partner on Device and CMC Development for Intranasal PTSD Drug SPC-15
SILO

GlobeNewswire

a year ago

Silo Pharma and Resyca BV Partner on Device and CMC Development for Intranasal PTSD Drug SPC-15

Silo Pharma Secures Exclusive Global License for Alzheimer's Therapeutic
SILO

GlobeNewswire

a year ago

Silo Pharma Secures Exclusive Global License for Alzheimer's Therapeutic

Silo Pharma Announces Exclusive, Global License for Lead Candidate SPC-15 Targeting PTSD and Stress-Induced Anxiety Disorders
SILO

GlobeNewswire

a year ago

Silo Pharma Announces Exclusive, Global License for Lead Candidate SPC-15 Targeting PTSD and Stress-Induced Anxiety Disorders

Silo Pharma Partners with AmplifyBio to Advance SPC-15 for PTSD and Anxiety
SILO

GlobeNewswire

a year ago

Silo Pharma Partners with AmplifyBio to Advance SPC-15 for PTSD and Anxiety

Silo Pharma Announces Successful Production of its SP-26 Ketamine Implant for Fibromyalgia
SILO

GlobeNewswire

a year ago

Silo Pharma Announces Successful Production of its SP-26 Ketamine Implant for Fibromyalgia

Silo Pharma Announces Closing of $2 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
SILO

GlobeNewswire

a year ago

Silo Pharma Announces Closing of $2 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules

Silo Pharma Announces $2 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
SILO

GlobeNewswire

a year ago

Silo Pharma Announces $2 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules

Silo Pharma Submits Pre-Investigational New Drug Application to FDA for SPC-15 as a Treatment for PTSD and Anxiety
SILO

GlobeNewswire

a year ago

Silo Pharma Submits Pre-Investigational New Drug Application to FDA for SPC-15 as a Treatment for PTSD and Anxiety

Silo Pharma Announces Positive Results from Study for Depression Treatment, Remission, and Relapse Prevention
SILO

GlobeNewswire

a year ago

Silo Pharma Announces Positive Results from Study for Depression Treatment, Remission, and Relapse Prevention

Silo Pharma to Participate in FDA Meeting Exploring Emerging Therapeutic Interest in Ketamine
SILO

GlobeNewswire

a year ago

Silo Pharma to Participate in FDA Meeting Exploring Emerging Therapeutic Interest in Ketamine

Silo Pharma Announces Positive Results for Intranasal PTSD Treatment
SILO

GlobeNewswire

a year ago

Silo Pharma Announces Positive Results for Intranasal PTSD Treatment

Silo Pharma set to Acquire Exclusive Licensing for Promising Alzheimer’s Disease Therapeutic
SILO

GlobeNewswire

a year ago

Silo Pharma set to Acquire Exclusive Licensing for Promising Alzheimer’s Disease Therapeutic

Silo Pharma Exercises Option for Exclusive License Agreement for First-in-Class PTSD and Stress-Induced Anxiety Therapeutic
SILO

GlobeNewswire

a year ago

Silo Pharma Exercises Option for Exclusive License Agreement for First-in-Class PTSD and Stress-Induced Anxiety Therapeutic

Silo Pharma Files Patent for Groundbreaking Ketamine Implant Therapeutic to Target Fibromyalgia and Chronic Pain
SILO

GlobeNewswire

a year ago

Silo Pharma Files Patent for Groundbreaking Ketamine Implant Therapeutic to Target Fibromyalgia and Chronic Pain

Silo Pharma Completes Successful Dose-Ranging Study of SPC-15 Intranasal Therapeutic for PTSD
SILO

GlobeNewswire

2 years ago

Silo Pharma Completes Successful Dose-Ranging Study of SPC-15 Intranasal Therapeutic for PTSD

Silo Pharma’s SP-26 Ketamine Implant Demonstrates Successful Drug Delivery
SILO

GlobeNewswire

2 years ago

Silo Pharma’s SP-26 Ketamine Implant Demonstrates Successful Drug Delivery

Silo Pharma Announces Pipeline Prioritization for 2024 Targeting Mental Health, Chronic Pain, and Neurology
SILO

GlobeNewswire

2 years ago

Silo Pharma Announces Pipeline Prioritization for 2024 Targeting Mental Health, Chronic Pain, and Neurology

Northann Corp.’s New 3-D Printing Ecosystem Products Receive “Best of” Innovation Awards at TISE2024
SILO

GlobeNewswire

2 years ago

Northann Corp.’s New 3-D Printing Ecosystem Products Receive “Best of” Innovation Awards at TISE2024

Uxin to Hold an Extraordinary General Meeting on March 1, 2024
SILO

PR Newswire

2 years ago

Uxin to Hold an Extraordinary General Meeting on March 1, 2024

SILO

Associated Press Finance

2 years ago

Mesa Air: Fiscal Q4 Earnings Snapshot

Mesa Air Group Reports Fourth Quarter and Fiscal Full-Year 2023 Results
SILO

GlobeNewswire

2 years ago

Mesa Air Group Reports Fourth Quarter and Fiscal Full-Year 2023 Results

NextPlay Received Notice From NASDAQ
SILO

NewMediaWire

2 years ago

NextPlay Received Notice From NASDAQ

Forbes-Approved: CareCloud is Streamlining Healthcare with Smart Technology for All Practices
SILO

GlobeNewswire

2 years ago

Forbes-Approved: CareCloud is Streamlining Healthcare with Smart Technology for All Practices

Silo Pharma Announces Positive Results in Alzheimer’s Disease Study
SILO

GlobeNewswire

2 years ago

Silo Pharma Announces Positive Results in Alzheimer’s Disease Study

Rent the Runway, Inc. (RENT) Upgraded to Buy: What Does It Mean for the Stock?
SILO

Zacks

2 years ago

Rent the Runway, Inc. (RENT) Upgraded to Buy: What Does It Mean for the Stock?

VCI Global Secures Its First IPO Consultancy Deal in 2024 With a Singapore-Based Fin-MedTech Medical Group
SILO

GlobeNewswire

2 years ago

VCI Global Secures Its First IPO Consultancy Deal in 2024 With a Singapore-Based Fin-MedTech Medical Group

Xos, Inc. Ranked Number 51 Fastest-Growing Company in North America on the 2023 Deloitte Technology Fast 500™
SILO

GlobeNewswire

2 years ago

Xos, Inc. Ranked Number 51 Fastest-Growing Company in North America on the 2023 Deloitte Technology Fast 500™

CareCloud Elevates Pathology Practice siParadigm with Cutting-Edge CareCloud Central Platform
SILO

GlobeNewswire

2 years ago

CareCloud Elevates Pathology Practice siParadigm with Cutting-Edge CareCloud Central Platform

Steakholder Foods Adds Plant-Based Shrimps to Expanding Range of 3D-Printed Seafood and Analogues
SILO

PR Newswire

2 years ago

Steakholder Foods Adds Plant-Based Shrimps to Expanding Range of 3D-Printed Seafood and Analogues

Meiwu Technology Co., Limited Regains Compliance with Nasdaq Listing Requirements
SILO

GlobeNewswire

2 years ago

Meiwu Technology Co., Limited Regains Compliance with Nasdaq Listing Requirements

Cohen & Company Capital Markets Highlights Strong 2023
SILO

PR Newswire

2 years ago

Cohen & Company Capital Markets Highlights Strong 2023

POET Technologies Provides Update on Non-Brokered Private Placement
SILO

GlobeNewswire

2 years ago

POET Technologies Provides Update on Non-Brokered Private Placement

Meta Materials Announces Proposed SEC Settlement
SILO

ACCESSWIRE

2 years ago

Meta Materials Announces Proposed SEC Settlement

Societal CDMO Reports Inducement Grants for New Staff
SILO

GlobeNewswire

2 years ago

Societal CDMO Reports Inducement Grants for New Staff

Silo Pharma Successfully Completes First Phase of Dose-Ranging Study of SPC-15 an Intranasal Treatment for PTSD
SILO

GlobeNewswire

2 years ago

Silo Pharma Successfully Completes First Phase of Dose-Ranging Study of SPC-15 an Intranasal Treatment for PTSD

Steakholder Foods crafts 3-D printed eel
SILO

Food Dive

2 years ago

Steakholder Foods crafts 3-D printed eel

POET Technologies Announces ZKTel as Customer and Collaborator
SILO

GlobeNewswire

2 years ago

POET Technologies Announces ZKTel as Customer and Collaborator

Kuke Music Holding Second Quarter 2023 Earnings: EPS: CN¥0.69 (vs CN¥0.13 in 2Q 2022)
SILO

Simply Wall St.

2 years ago

Kuke Music Holding Second Quarter 2023 Earnings: EPS: CN¥0.69 (vs CN¥0.13 in 2Q 2022)

Silo Pharma and Partner Receive Regulatory Approval to Begin Development of Ketamine Implant for Fibromyalgia
SILO

GlobeNewswire

2 years ago

Silo Pharma and Partner Receive Regulatory Approval to Begin Development of Ketamine Implant for Fibromyalgia

Entera Bio Announces Closing of Private Placement - Extends Cash Runway into 2025
SILO

GlobeNewswire

2 years ago

Entera Bio Announces Closing of Private Placement - Extends Cash Runway into 2025

Immuron Clinical Trials Update
SILO

GlobeNewswire

2 years ago

Immuron Clinical Trials Update

Equillium Announces Update on Multi-Cytokine Inhibitors EQ101 & EQ102 in Development for Alopecia Areata and Celiac Disease
SILO

Business Wire

2 years ago

Equillium Announces Update on Multi-Cytokine Inhibitors EQ101 & EQ102 in Development for Alopecia Areata and Celiac Disease

RENN Fund, Inc. Announces Year End Distribution
SILO

ACCESSWIRE

2 years ago

RENN Fund, Inc. Announces Year End Distribution

Locafy Announces First Subscription Contract from Agreement with U.S.-Based Media Publisher
SILO

GlobeNewswire

2 years ago

Locafy Announces First Subscription Contract from Agreement with U.S.-Based Media Publisher

Science 37 Receives Top Honors in Everest PEAK Matrix®
SILO

GlobeNewswire

2 years ago

Science 37 Receives Top Honors in Everest PEAK Matrix®

Genius Group Launches AI Education Ecosystem in Partnership with FatBrain AI
SILO

GlobeNewswire

2 years ago

Genius Group Launches AI Education Ecosystem in Partnership with FatBrain AI

Science 37 Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
SILO

GlobeNewswire

2 years ago

Science 37 Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)

Iterum Therapeutics Regains Compliance with Nasdaq Bid Price Rule
SILO

GlobeNewswire

2 years ago

Iterum Therapeutics Regains Compliance with Nasdaq Bid Price Rule

Immuron Announces First Patients Enrolled in Campylobacter Challenge Clinical Study
SILO

GlobeNewswire

2 years ago

Immuron Announces First Patients Enrolled in Campylobacter Challenge Clinical Study

Dyadic Announces Top-Line Results from its Successful Phase 1 Clinical Trial for a First-in-Human Filamentous Fungal-Based Vaccine Candidate
SILO

GlobeNewswire

2 years ago

Dyadic Announces Top-Line Results from its Successful Phase 1 Clinical Trial for a First-in-Human Filamentous Fungal-Based Vaccine Candidate

Iridex Corporation Announces Successful Appeal for Revision of Recent Medicare LCDs to Provide Broader Coverage of Cyclophotocoagulation
SILO

GlobeNewswire

2 years ago

Iridex Corporation Announces Successful Appeal for Revision of Recent Medicare LCDs to Provide Broader Coverage of Cyclophotocoagulation

Deswell Industries (NASDAQ:DSWL) Has Affirmed Its Dividend Of $0.10
SILO

Simply Wall St.

2 years ago

Deswell Industries (NASDAQ:DSWL) Has Affirmed Its Dividend Of $0.10

Phoenix Wins Contract Under Florida Sheriffs Association Cooperative Purchasing Program for Electric School Buses
SILO

ACCESSWIRE

2 years ago

Phoenix Wins Contract Under Florida Sheriffs Association Cooperative Purchasing Program for Electric School Buses

Splash Beverage Group’s Copa di Vino and Pulpoloco Sangrias to be Featured in AMPM’s Thorntons Convenience Stores
SILO

GlobeNewswire

2 years ago

Splash Beverage Group’s Copa di Vino and Pulpoloco Sangrias to be Featured in AMPM’s Thorntons Convenience Stores

Silo Pharma Enters into Exclusive License Agreement with Medspray Pharma BV for Intranasal Technology used in SPC-15 Treatment for PTSD
SILO

GlobeNewswire

2 years ago

Silo Pharma Enters into Exclusive License Agreement with Medspray Pharma BV for Intranasal Technology used in SPC-15 Treatment for PTSD

The Glimpse Group, Inc. (NASDAQ:VRAR) Q1 2024 Earnings Call Transcript
SILO

Insider Monkey

2 years ago

The Glimpse Group, Inc. (NASDAQ:VRAR) Q1 2024 Earnings Call Transcript

Splash Beverage Groups Copa di Vino Brand Received Walmart’s Coveted Golden Ticket Award for Its Lineup of Premium Single Serve Wine
SILO

GlobeNewswire

2 years ago

Splash Beverage Groups Copa di Vino Brand Received Walmart’s Coveted Golden Ticket Award for Its Lineup of Premium Single Serve Wine

Genius Group Launches Exponential Entrepreneur Awards in Partnership with OpenExO
SILO

GlobeNewswire

2 years ago

Genius Group Launches Exponential Entrepreneur Awards in Partnership with OpenExO

SILO

Business Wire

2 years ago

ENDRA Life Sciences Reports Third Quarter 2023 Financial Results and Provides Business Update

OLB Group to Conduct Second Quarter Earnings Call November 15
SILO

ACCESSWIRE

2 years ago

OLB Group to Conduct Second Quarter Earnings Call November 15

Acon receives first FDA clearance for over-the-counter COVID-19 antigen test
SILO

MedTech Dive

2 years ago

Acon receives first FDA clearance for over-the-counter COVID-19 antigen test

Lightbridge Comments on Recent Nuclear Industry News
SILO

GlobeNewswire

2 years ago

Lightbridge Comments on Recent Nuclear Industry News

Eledon Pharmaceuticals to Present at Jefferies London Healthcare Conference
SILO

GlobeNewswire

2 years ago

Eledon Pharmaceuticals to Present at Jefferies London Healthcare Conference

Silo Pharma to Initiate Dose-Ranging Study of Novel Intranasal Therapeutic SPC-15 for the Treatment of PTSD
SILO

GlobeNewswire

2 years ago

Silo Pharma to Initiate Dose-Ranging Study of Novel Intranasal Therapeutic SPC-15 for the Treatment of PTSD

Predictive Oncology to Report Third Quarter 2023 Financial Results and Host Conference Call and Webcast on Tuesday, November 14, 2023
SILO

GlobeNewswire

2 years ago

Predictive Oncology to Report Third Quarter 2023 Financial Results and Host Conference Call and Webcast on Tuesday, November 14, 2023

SemiLEDs to Announce Fiscal Fourth Quarter and Fiscal Year Ended 2023 Financial Results on Friday, November 10, 2023
SILO

Business Wire

2 years ago

SemiLEDs to Announce Fiscal Fourth Quarter and Fiscal Year Ended 2023 Financial Results on Friday, November 10, 2023

Duos Technologies Group Sets Third Quarter 2023 Earnings Call for Tuesday, November 14, 2023 at 4:30 PM ET
SILO

GlobeNewswire

2 years ago

Duos Technologies Group Sets Third Quarter 2023 Earnings Call for Tuesday, November 14, 2023 at 4:30 PM ET

Share on Social Networks: